title: New drugs for follicular lymphoma.
abstract: Despite the improvement in prognosis since the advent of rituximab, follicular lymphoma is still incurable and remains the cause of death of most afflicted patients. With the expanding knowledge of the pathogenesis of B-cell malignancies, in the last few years a plethora of new therapies acting through a variety of mechanisms have shown promising results. This review attempts to analyze the evidence available on these new drugs, which include new monoclonal antibodies and immunoconjugates, the anti-angiogenic and immunomodulatory agent lenalidomide, the proteasome inhibitor bortezomib, inhibitors of B-cell receptor pathway enzymes, such as ibrutinib, idelalisib, duvelisib and entospletinib, BCL2 inhibitors and checkpoint inhibitors. We conclude that despite the high expectations around the new therapeutic options for patients with refractory disease, these new drugs have side effects that require caution with their use, particularly in light of the still short follow up and the lack of both randomized trials and data on combination regimens.
authors.affiliation: Department of Hematology, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain.
authors.forename: Marc
authors.initials: M
authors.lastname: Sorigue
authors.affiliation: Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Spain.
authors.forename: Josep-Maria
authors.initials: JM
authors.lastname: Ribera
authors.affiliation: Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Motlló
authors.affiliation: Department of Clinical Hematology, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Spain. Electronic address: jsancho@iconcologia.net.
authors.forename: Juan-Manuel
authors.initials: JM
authors.lastname: Sancho
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D016879:Salvage Therapy / Q000009:adverse effects / Q000379:methods / Q000639:trends
chemical_list: D000970:Antineoplastic Agents
keywords: Follicular lymphoma; New therapies; Small molecules; Targeted drugs; Treatment